Abbisko Therapeutics to Present Phase 3 Pimicotinib Results at 2025 ASCO Meeting

Abbisko Cayman Limited ( (HK:2256) ) has provided an update.

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, will present the results of its phase 3 study on pimicotinib at the 2025 ASCO Annual Meeting. This presentation will cover the efficacy, safety, and clinical outcomes of pimicotinib in treating TGCT, potentially impacting Abbisko’s market positioning and stakeholder interests, especially given the drug’s breakthrough therapy designations.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited operates in the pharmaceutical industry, focusing on developing innovative therapies. Its primary product, pimicotinib, is a small molecule CSF-1R inhibitor aimed at treating Tenosynovial Giant Cell Tumor (TGCT). The company has a market focus on breakthrough therapies, with pimicotinib receiving designations from regulatory bodies in China, the US, and Europe.

Average Trading Volume: 6,165,422

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.89B

For an in-depth examination of 2256 stock, go to TipRanks’ Stock Analysis page.